This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JNJ Vaccine Pause Gives Stay-at-Home ETFs a Shot in the Arm
by Sweta Killa
The U.S. regulators recommended an immediate pause on the use of Johnson & Johnson's (JNJ) COVID- 19 vaccine over reports of a "rare and severe type of blood clot" in six out of millions vaccinated.
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
by Zacks Equity Research
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Stock Market News for Apr 14, 2021
by Zacks Equity Research
The S&P 500 and the Nasdaq closed in the green on Tuesday backed by solid gains in tech stocks.
Which Vaccine Maker Will Win the Fight Against COVID-19?
by Kinjel Shah
A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.
J&J (JNJ) COVID-19 Jab to be Paused on FDA/CDC Recommendation
by Zacks Equity Research
FDA/CDC said that rare and severe blood clots accompanied by low levels of blood platelets have been identified in six individuals who received J&J's (JNJ) COVID-19 vaccine.
S&P 500 Hits Another New All-Time High
by Mark Vickery
The index's totals weren't super-noteworthy in the daily performance, +0.33%, but this April has seen multiple new highs four of the past six sessions.
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study
by Zacks Equity Research
Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.
Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study
by Zacks Equity Research
Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.
Consumer Price Index Rise 0.6%
by Zacks Equity Research
Consumer Price Index Rise 0.6%
CPI +0.6%: Higher, but Not Scary; JNJ Vax on Hold?
by Mark Vickery
Headline CPI last month reached +0.6%, 10 basis points ahead of consensus, and the highest single-month tally since June of 2009.
Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study
by Zacks Equity Research
Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Stock Market News for Apr 12, 2021
by Zacks Equity Research
Benchmarks hit record levels on Friday, closing in the green for consecutive weeks as investors shrugged off inflation fears and focused on quarterly earnings season amid reopening optimism
J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots
by Zacks Equity Research
The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.
Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
by Zacks Equity Research
Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.
ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data
by Zacks Equity Research
ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.
Higher-Than-Expected PPI in March
by Zacks Equity Research
Higher-Than-Expected PPI in March.
Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study
by Zacks Equity Research
Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.
PPI Doubles Month Over Month to 1.0%
by Mark Vickery
We haven't seen a higher headline PPI figure since the fallout of the pandemic era, now more than a year ago.
Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots
by Zacks Equity Research
European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.
Earnings Estimates Rising for Moderna (MRNA): Will It Gain?
by Zacks Equity Research
Moderna (MRNA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study
by Zacks Equity Research
Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.
Company News for Apr 7, 2021
by Zacks Equity Research
Companies in The News Are: ILMN, NVAX, MRNA, BP.